Étude BAY 16443 : étude de phase 1, en escalade de dose, évaluant la tolérance du BAY 1163877, un inhibiteur de FGFR, chez des patients ayant une tumeur solide réfractaire localement avancée ou métastatique. [essai clos aux inclusions] BAY 16443 : Etude de phase I, ouverte, non-randomisée, d'escalade de dose, destinée à évaluer l'innocuité, la tolérance, les pharmacocinétiques et la dose maximale tolérée de BAY 1163877 chez des pati...

• Country France
• organs Tumeurs solides
• Specialty Thérapies Ciblées

A study to test the safety and effectiveness of Bay 41-6551 as additional therapy to standard of care antimicrobial treatment in patients who have Gram-Negative Pneumonia and are intubated and mechanially ventilated To demonstrate that as adjunctive therapy to IV antibiotics, BAY 41-6551 400 mg (amikacin as free base) administered as an aerosol by the PDDS Clinical every 12 hours is safe and more effective than p...

• Country None
• organs None
• Specialty None

Efficacy and safety of riociguat in patients with high blood pressure in the blood vessels of the lungs associated with interstitial pneumonias of unknown cause To evaluate the efficacy and safety of 26-weeks of treatment with riociguat vs. placebo in patients with symptomatic PH associated with IIP

• Country None
• organs None
• Specialty None

A clinical trial to compare the safety of moxifloxacin given as infusion in the vein and as tablet to the safety of another treatment regimen in patients with a complicated infection of the abdominal cavity To evaluate the safety of treatment with moxifloxacin (compared to the safety of IV ertapenem followed by PO amoxicillin/clavulanate)

• Country None
• organs None
• Specialty None

A multi-center, double-blind, double-dummy, randomized, controlled, parallel-group study to assess efficacy and safety of SH T00658ID compared to SH D593B in the treatment of primary dysmenorrhea The primary objective of this study is to show superiority of SH T00658ID over SH D593B with respect to the number of days with dysmenorrheic pain in a defined period, i.e. comparison between two bas...

• Country None
• organs None
• Specialty None

Randomized phase II study of roniciclib vs placebo in subjects receiving chemotherapy for SCLC Roniciclib és placebo randomizált, II. fázisú vizsgálata kissejtes tüdőrákban szenvedő, kemoterápiával kezelt betegeknél The primary objective is to compare roniciclib with placebo in addition to background treatment with chemotherapy (either cisplatin + etoposide or carboplatin + etoposide) in terms of progression free...

• Country None
• organs None
• Specialty None

A randomized, , double-blind, single centre, intra-individual comparison study with repeated application to assess the wound-healing efficacy of a 5 % Dexpanthenol ointment compared with placebo in patients with superficial, abrasive wounds Re-epithelization day 5

• Country None
• organs None
• Specialty None

Long-term study to collect additional information to evaluate the saftey and tolerability of BAY 63-2521 in different doses To investigate the safety, tolerability, and feasibility of individual titration of BAY 63 2521 according to peripheral systolic blood pressure. In addition, long term safety and tolerability of BAY ...

• Country None
• organs None
• Specialty None

A randomized controlled study of BAY 43-9006 in combination with doxorubicin versus doxorubicin in patients with advanced hepatocellular carcinoma The primary objective is to evaluate the effect of doxorubicin plus sorafenib or doxorubicin plus placebo on time to progression (TTP) in patients with advanced hepatocellular carcinoma

• Country None
• organs None
• Specialty None

Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) - a fixed-dose, double-blind, raNdomized multi-center Trial - POTENT I The primary objective of this study is to compare the efficacy and safety of vardenafil ODT 10 mg (PRN) after 12 weeks of treatment or LOCF with placebo in a general population of men with erectile dy...

• Country None
• organs None
• Specialty None